Should I buy or sell Mirum Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares. View MIRM analyst ratings or view top-rated stocks .

What is Mirum Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued twelve-month target prices for Mirum Pharmaceuticals' shares. Their MIRM share price targets range from $37.00 to $77.00. On average, they expect the company's stock price to reach $54.78 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price. View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts .

How have MIRM shares performed in 2023?

Mirum Pharmaceuticals' stock was trading at $19.50 on January 1st, 2023. Since then, MIRM shares have increased by 62.6% and is now trading at $31.70. View the best growth stocks for 2023 here .

When is Mirum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024. View our MIRM earnings forecast .

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) issued its earnings results on Thursday, November, 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.07. The firm earned $47.73 million during the quarter, compared to analyst estimates of $34.31 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 79.52% and a negative net margin of 113.45%.

What ETFs hold Mirum Pharmaceuticals' stock?

ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) . Virtus LifeSci Biotech Products ETF (BBP) .

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE) , Fulcrum Therapeutics (FULC) , OPKO Health (OPK) , Vaxart (VXRT) , Advanced Micro Devices (AMD) , Matinas BioPharma (MTNB) , Sorrento Therapeutics (SRNE) , Trevena (TRVN) , VBI Vaccines (VBIV) and Dynavax Technologies (DVAX) .

When did Mirum Pharmaceuticals IPO?

(MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Who are Mirum Pharmaceuticals' major shareholders?

Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (8.49%), Cadian Capital Management LP (3.08%), Polar Capital Holdings Plc (2.52%), Avidity Partners Management LP (2.45%), Adage Capital Partners GP L.L.C. (1.43%) and William Blair Investment Management LLC (1.14%). Insiders that own company stock include Christopher Peetz , Eric Bjerkholt, Ian Clements , James E Flynn , John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig , Patrick J Heron and Peter Radovich. View institutional ownership trends .

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Mirum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:MIRM)

$31.70

-0.30 (-0.94%)

(As of 12/4/2023 ET)

Compare

Today's Range: $30.97
▼
$32.31
50-Day Range: $27.14
▼
$32.35
52-Week Range: $17.49
▼
$33.39

Volume: 644,779 shs
Average Volume: 496,077 shs
Market Capitalization: $1.48 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $54.78

Mirum Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.13 Rating Score
Upside/Downside: 72.8% Upside
$54.78 Price Target
Short Interest: Bearish
13.64% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.69
Upright™ Environmental Score
News Sentiment: 0.62
Based on 2 Articles This Week
Insider Trading: Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth: Growing
From ($2.45) to ($0.23) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

301st out of 952 stocks

Pharmaceutical Preparations Industry

128th out of 434 stocks

4.6

Analyst's Opinion

Consensus Rating
Mirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $54.78, Mirum Pharmaceuticals has a forecasted upside of 72.8% from its current price of $31.70.
Amount of Analyst Coverage
Mirum Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
13.64% of the outstanding shares of Mirum Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Mirum Pharmaceuticals has recently increased by 4.61%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Mirum Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Mirum Pharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Mirum Pharmaceuticals has received a 61.01% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Mirum Pharmaceuticals is -1.69.

1.5

News and Social Media Coverage

News Sentiment
Mirum Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Mirum Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 3 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mirum Pharmaceuticals insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $438,516.00 in company stock and sold $454,912.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.
Percentage Held by Insiders
24.06% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($2.45) to ($0.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mirum Pharmaceuticals is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mirum Pharmaceuticals is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mirum Pharmaceuticals has a P/B Ratio of 8.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

MIRM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MIRM Stock News Headlines

December 4, 2023 | benzinga.com

Mirum Pharmaceuticals Stock (NASDAQ:MIRM) Insider Trades

November 28, 2023 | americanbankingnews.com

Mirum Pharmaceuticals' (MIRM) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 22, 2023 | morningstar.com

Mirum Pharmaceuticals Inc MIRM

November 20, 2023 | finance.yahoo.com

Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

November 20, 2023 | markets.businessinsider.com

11 Analysts Have This to Say About Mirum Pharmaceuticals

November 14, 2023 | msn.com

Morgan Stanley Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Overweight Recommendation

November 13, 2023 | markets.businessinsider.com

Mirum Pharmaceuticals’ Growing Momentum: Livmarli’s Continued Success and Expansion Opportunities in Rare Liver Diseases Market

December 4, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 13, 2023 | finance.yahoo.com

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

November 6, 2023 | markets.businessinsider.com

Mirum Pharmaceuticals: Strong Q3 Performance and Future Growth Potential Reinforce Buy Rating

November 6, 2023 | markets.businessinsider.com

Optimistic Outlook for Mirum Pharmaceuticals: Strong Financial Performance and Potential Market Unlocking

November 6, 2023 | finance.yahoo.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Call Transcript

November 2, 2023 | finance.yahoo.com

Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023 | benzinga.com

Earnings Outlook For Mirum Pharmaceuticals

November 1, 2023 | msn.com

Mirum Pharmaceuticals Q3 2023 Earnings Preview

October 30, 2023 | finance.yahoo.com

Mirum Pharmaceuticals to Present New Data at The Liver Meeting®

October 27, 2023 | finance.yahoo.com

Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023

October 25, 2023 | msn.com

Cantor starts Mirum at overweight, sees peak sales of over $1B

October 24, 2023 | msn.com

Cantor Fitzgerald Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Overweight Recommendation

October 19, 2023 | markets.businessinsider.com

Buy Rating Maintained for Mirum Pharmaceuticals Despite FDA Delays: An Analysis by Leerink Partners

October 18, 2023 | msn.com

Evercore ISI Group Reiterates Mirum Pharmaceuticals (MIRM) Outperform Recommendation

October 18, 2023 | markets.businessinsider.com

FDA Extension on Mirum’s Livmarli sNDA Review: Minimal Impact and Potential Approval on the Horizon

October 18, 2023 | markets.businessinsider.com

Positive Outlook for Mirum Pharmaceuticals: Ed Arce’s Buy Rating Justified by LIVMARLI’s Potential and Solid MARCH-PFIC Trial Results

October 17, 2023 | finance.yahoo.com

Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

October 14, 2023 | seekingalpha.com

Mirum Pharmaceuticals to sell 7.94M shares for holders

October 10, 2023 | msn.com

JMP Securities Reiterates Mirum Pharmaceuticals (MIRM) Market Outperform Recommendation

See More Headlines

Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MIRM
CUSIP: N/A
CIK: 1759425
Web: mirumpharma.com
Phone: (650) 667-4085
Fax: N/A
Employees: 249
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $54.78
High Stock Price Target: $77.00
Low Stock Price Target: $37.00
Potential Upside/Downside: +72.8%
Consensus Rating: Buy
Rating Score (0-4): 3.13
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-135,660,000.00
Net Margins: -113.45%
Pretax Margin: -112.82%
Return on Equity: -79.52%
Return on Assets: -28.17%

Debt

Debt-to-Equity Ratio: 1.14
Current Ratio: 5.20
Quick Ratio: 4.91

Sales & Book Value

Annual Sales: $144.73 million
Price / Sales: 10.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.85 per share
Price / Book: 8.23

Miscellaneous

Outstanding Shares: 46,614,000
Free Float: 35,399,000
Market Cap: $1.48 billion
Optionable: Not Optionable
Beta: 1.21

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Christopher Peetz (Age 44)
President, CEO & Director
Comp: $1.09M
Mr. Peter Radovich M.B.A. (Age 45)
Ph.D., Chief Operating Officer
Comp: $732.15k
Dr. Pamela Vig Ph.D. (Age 52)
Head of R&D
Comp: $678.2k
Ms. Lara Longpre MBA (Age 53)
MSC, Chief Development Officer
Comp: $678.2k
Mr. Eric H. Bjerkholt M.B.A. (Age 63)
Chief Financial Officer
Andrew McKibben
Vice President of Investor Relations and Finance
Mr. Paul K. Ross
Chief Compliance Officer
Ms. Erin Campany (Age 55)
Senior Vice President of Human Resources
Dr. Ian Clements Ph.D. (Age 54)
Consultant
Comp: $649.1k
Ms. Vinita P. Kumar
Senior vice President of Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MIRM Stock Analysis - Frequently Asked Questions

Should I buy or sell Mirum Pharmaceuticals stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings or view top-rated stocks.
What is Mirum Pharmaceuticals' stock price target for 2024?: 8 equities research analysts have issued twelve-month target prices for Mirum Pharmaceuticals' shares. Their MIRM share price targets range from $37.00 to $77.00. On average, they expect the company's stock price to reach $54.78 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price.
View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts.
How have MIRM shares performed in 2023?: Mirum Pharmaceuticals' stock was trading at $19.50 on January 1st, 2023. Since then, MIRM shares have increased by 62.6% and is now trading at $31.70.
View the best growth stocks for 2023 here.
When is Mirum Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our MIRM earnings forecast.
How were Mirum Pharmaceuticals' earnings last quarter?: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) issued its earnings results on Thursday, November, 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.07. The firm earned $47.73 million during the quarter, compared to analyst estimates of $34.31 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 79.52% and a negative net margin of 113.45%.
What ETFs hold Mirum Pharmaceuticals' stock?: ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP).

What other stocks do shareholders of Mirum Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).
When did Mirum Pharmaceuticals IPO?: (MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.
Who are Mirum Pharmaceuticals' major shareholders?: Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (8.49%), Cadian Capital Management LP (3.08%), Polar Capital Holdings Plc (2.52%), Avidity Partners Management LP (2.45%), Adage Capital Partners GP L.L.C. (1.43%) and William Blair Investment Management LLC (1.14%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich.
View institutional ownership trends.
How do I buy shares of Mirum Pharmaceuticals?: Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MIRM) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial